Episode 338: 337. What is the ideal Vitamin D Level to target?

Episode 338: 337. What is the ideal Vitamin D Level to target?

In 2011, the Endocrine Society published a guideline on “Evaluation, Treatment, and Prevention of Vitamin D Deficiency”

Now, the Society has issued an updated guideline, Demay MB et al. Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2024 Aug; 109:1907. (https://doi.org/10.1210/clinem/dgae290)

Previously, the Endocrine Society had labeled vitamin D status as “deficient” when serum hydroxyvitamin D (25[OH]D) was lower than 20 ng/mL, and “insufficient” when serum 25(OH)D was 20 ng/mL to 29 ng/mL. Now, the Society “no longer endorses specific 25(OH)D levels to define vitamin D sufficiency, insufficiency, and deficiency.”

Why is that--- because no clinical research has not established distinct thresholds of serum levels that can be tied confidently to specific clinical outcomes.

In the general population of adults (age range, 19–74), neither routine vitamin D supplementation nor routine testing of 25(OH)D levels are recommended.

What about >75—NOT RECOMMENDED! They do suggest vit sup for possible to lower mortality but acknowledge that this effect was small and bordline statistical significance ___ relative risk, 0.96; 95% confidence interval, 0.93–1.00 – to it hit the line of no effect on flawed bias studies! Come on!!!!!

An evidence review showed no conclusive evidence that supplementation lowered risks for fractures, falls, or infections in this age group

The common practice of ordering routine 25(OH)D levels is not recommended,. Obtaining serum 25(OH)D levels in relatively healthy people and prescribing vitamin D supplements to get levels ≥30 ng/mL (or even higher) is not supported by this guideline.

FINALLY—you want to give then go ahead and give a reasonable amount but don’t test. Don’t research. Don’t target a level. JUST DONT


Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(397)

Episode 435: 442. 7 article review

Episode 435: 442. 7 article review

we unpack whether rivaroxaban followed by aspirin improves thromboprophylaxis after hip and knee arthroplasty, put oral GLP-1 therapy orforglipron head-to-head with dapagliflozin for type 2 diabetes, ...

10 Sep 33min

Episode 434: 441. Coronary Artery Calcium (CAC) -- Yacky Yack, the details on CAC

Episode 434: 441. Coronary Artery Calcium (CAC) -- Yacky Yack, the details on CAC

Does a Coronary Artery Calcium (CAC) scan still earn its place in modern cardiovascular prevention? This podcast cuts through the headlines to examine the recent research, challenge overconfident conc...

31 Aug 48min

Episode 433: 440. CME Understanding Medical Stats

Episode 433: 440. CME Understanding Medical Stats

OMED lecture on how to understand medical stats

21 Aug 33min

Episode 432: 439. 6 articles in 2026

Episode 432: 439. 6 articles in 2026

CME

24 Juli 25min

Episode 431: 438. CME- What To Do AFTER PE Diagnosis

Episode 431: 438. CME- What To Do AFTER PE Diagnosis

OMED lecture

21 Juli 26min

Episode 430: edit fix 437. A Brief Review of the Medical Literature!

Episode 430: edit fix 437. A Brief Review of the Medical Literature!

Xin X, et al. Optimal exercise modalities and dosages for blood pressure reduction in adults with prehypertension and established hypertension: A network meta-analysis and dose–response relationship s...

8 Juli 32min

Episode 429: 436. postpartum burnout., asundexian, semaglutide and ETOH, neck infection, varenicline

Episode 429: 436. postpartum burnout., asundexian, semaglutide and ETOH, neck infection, varenicline

Jafari K, et al. Risk factors for pediatric deep neck infection revisit after emergency department discharge for pharyngitis or localized neck symptoms. Ann Emerg Med 2026 May; 87:605. DOI: 10.1016/j....

15 Juni 31min

Episode 428: 435. Evolocumab, Statin and CKD, PCN allergy, MRI vs Rotator Cuff

Episode 428: 435. Evolocumab, Statin and CKD, PCN allergy, MRI vs Rotator Cuff

https://pubmed.ncbi.nlm.nih.gov/41903215/  Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV ...

8 Maj 17min

Populärt inom Hälsa

somna-med-henrik
rss-jossan-nina
rss-bara-en-till-om-beroende-medberoende
inga-beiga-morsor
bullfika
rss-vuxna-pa-latsas
not-fanny-anymore
sexnoveller-deluxe
johannes-hansen-podcast
rss-viktmedicinpodden
rss-hos-psykologen
sa-in-i-sjalen
angestpodden
rss-angra-inget-3
rss-basta-livet
sova-med-dan-horning
rss-autismandan
rss-ronden
rss-traningsklubben
tyngre-radio